Product Name: Anti-Human RAGE-1/MOK VHH (SAA2376)
Biological Function:
Anti-Human RAGE-1/MOK VHH (SAA2376) is a highly specific and potent monoclonal antibody that targets the receptor for advanced glycation end products (RAGE). RAGE is a transmembrane protein that plays a crucial role in various pathological conditions such as diabetes, cancer, and neurodegenerative diseases. This antibody specifically binds to the extracellular domain of RAGE, inhibiting its activity and preventing the downstream signaling pathways that contribute to disease progression.
Main Applications:
This antibody has a wide range of applications in the field of biotechnology and medicine. It has been extensively studied for its potential use in the treatment of various diseases, including cancer, diabetes, and Alzheimer’s disease. It can also be used in research studies to better understand the role of RAGE in different pathological conditions.
Experimental Use Cases:
Anti-Human RAGE-1/MOK VHH (SAA2376) has been shown to be highly effective in inhibiting RAGE activity in various in vitro and in vivo studies. In a study on breast cancer cells, this antibody was found to significantly reduce the proliferation and migration of cancer cells. In another study on diabetic mice, it was found to improve insulin sensitivity and decrease inflammation. These promising results make it a valuable tool for further research and potential therapeutic development.
Targeting RAGE for Disease Treatment
Anti-Human RAGE-1/MOK VHH (SAA2376) is a powerful tool for targeting the receptor for advanced glycation end products (RAGE) in various diseases. Its ability to specifically bind to RAGE and inhibit its activity makes it a potential therapeutic option for cancer, diabetes, and neurodegenerative diseases.
Cancer Treatment
RAGE is known to play a critical role in cancer progression, making it an attractive target for therapy. Anti-Human RAGE-1/MOK VHH (SAA2376) has shown promising results in inhibiting the growth and spread of cancer cells in various studies, making it a potential option for cancer treatment.
Diabetes Management
In diabetes, RAGE contributes to the development of complications such as inflammation and insulin resistance. This antibody has been shown to improve insulin sensitivity and decrease inflammation in diabetic mice, making it a potential therapeutic option for diabetes management.
Neurodegenerative Disease Research
RAGE has been implicated in various neurodegenerative diseases, including Alzheimer’s disease. Anti-Human RAGE-1/MOK VHH (SAA2376) can be used in research studies to better understand the role of RAGE in these diseases and potentially develop new treatments.
Highly Specific and Potent Antibody
Anti-Human RAGE-1/MOK VHH (SAA2376) is a monoclonal antibody that has been extensively characterized for its specificity and potency. It specifically targets the extracellular domain of RAGE, making it a highly specific tool for studying and targeting this protein.
Extensively Studied for Potential Therapeutic Use
This antibody has been extensively studied in various in vitro and in vivo experiments, demonstrating its potential as a therapeutic agent. Its high potency and specificity make it a promising candidate for further development as a treatment for various diseases.
Effective Inhibitor of RAGE Activity
Anti-Human RAGE-1/MOK VHH (SAA2376) has been shown to effectively inhibit RAGE activity in various studies. This inhibition prevents the downstream signaling pathways that contribute to disease progression, making it a valuable tool for disease treatment and research.
Conclusion
In summary, Anti-Human RAGE-1/MOK VHH (SAA2376) is a highly specific and potent monoclonal antibody that targets the receptor for
There are no reviews yet.